OakChart

Annovis Bio Inc

ANVSHealthcare·Biotechnology·USA·Nano·NYSE·Nov 11 • 3:59 PM ET

0.8533-0.0210 (-2.40%)
2026-11-12 04:14 CET
Market cap
36.42 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-49.52 USD m
Free cash flow, TTM
-43.34 USD m
EPS diluted, TTM
-1.79
P/E
-
Compare

Price

ANVS against its 20, 50 and 200-day averages
2050200beatmiss
0.501.001.502.002.5015.4M30.9MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ANVSclose 0.8520-day 0.9850-day 1.13200-day 1.830.8552w low

84.5% under the 52-week high of 5.50 on 28 Nov 2025. 52-week low 0.62 on 5 Nov 2026. Last 15 sessions, 126.5% high to low

Volume 0.97× normal · the line is the 50-bar volume average

Profile

ANVS
52-week range, 5% of the way up
0.625.50

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Employees8
IPOJan 29, 2020
Beta1.37
ATR, 14d0.14
Rel volume0.97
Short float14.23%
Insider own11.79%
Inst own31.88%

Snapshot

6 groups

Valuation

Index-
Market Cap36.41M
Enterprise Value17.68M
Income-49.52M
Sales0.00M
Book/sh-0.10
Cash/sh0.44
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPOJan 29, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C1.94
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.47
Current Ratio3.47
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.79
EPS next Y-0.97
EPS next Q-0.30
EPS this Y-0.48%
EPS next Y31.04%
EPS next 5Y-2.67%
EPS past 3/5Y23.23% -10.15%
Sales past 3/5Y- -
EPS Y/Y TTM11.96%
Sales Y/Y TTM-
EPS Q/Q-23.75%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.11.76% -

Ownership

Insider Own11.79%
Insider Trans100.88%
Inst Own31.88%
Inst Trans2.98%
ROA-227.74%
ROE-703.68%
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-13.00%
SMA50-24.24%
SMA200-53.49%
Trades-

Technical

Shs Outstand42.61M
Shs Float37.65M
Short Float14.23%
Short Ratio3.20
Short Interest5.36M
52W High5.50 -84.49%
52W Low0.62 38.50%
Volatility24.56% 13.23%
ATR (14)0.14
RSI (14)41.14
Beta1.37
Rel Volume0.97
Avg Volume1.67M
Volume1,619,218

Performance

Perf Week-29.48%
Perf Month-19.50%
Perf Quarter-52.33%
Perf Half Y-61.56%
Perf YTD-75.34%
Perf Year-59.56%
Perf 3Y-85.29%
Perf 5Y-97.38%
Perf 10Y-
Recom1.00
Target Price10.50
Prev Close0.87
Price0.85
Change %-2.40%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Jul 08, 2026InitiatedRRoth CapitalBuy$8+837.5%
Feb 10, 2025DowngradeDD. Boral CapitalBuy → Hold
Oct 25, 2024UpgradeMMaxim GroupHold → Buy$25+2,829.8%
Dec 29, 2023InitiatedCCanaccord GenuityBuy$36+4,118.9%
Jul 07, 2021ReiteratedMMaxim GroupBuy$45 → $150+17,478.8%

Peers

Mkt cap
TickerCompanyMkt cap
CGTXCognition Therapeutics Inc64.42M
CRVOCervoMed Inc26.78M
INMBINmune Bio Inc34.05M
AVXLAnavex Life Sciences Corp98.26M
ATHEAlterity Therapeutics Ltd ADR44.12M
ABOSAcumen Pharmaceuticals Inc16.64M
PMNProMIS Neurosciences Inc33.72M
ACIUAC Immune SA230.01M
ALZNAlzamend Neuro Inc6.32M
PRTAProthena Corp Plc448.28M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Hoffman Michael BDirectorNov 06 '26Buy1.005,000,0005,000,0008,364,883Nov 06 04:30 PM
Hoffman Michael BDirectorMay 20 '26Buy1.8776,344142,7793,364,883May 21 08:11 PM
Hoffman Michael BDirectorApr 02 '26Buy2.10713,8001,498,9803,288,539Apr 03 05:06 PM
White Mark K.DirectorApr 02 '26Proposed Sale2.087,14214,848Apr 02 04:39 PM
Hoffman Michael BDirectorDec 08 '25Buy4.3145,000193,7942,574,739Dec 08 08:05 PM
Hoffman Michael BDirectorNov 24 '25Buy4.0839,200159,8862,519,739Nov 25 12:26 PM
Hoffman Michael BDirectorNov 21 '25Buy3.5020,00069,9002,490,539Nov 21 07:57 PM
Hoffman Michael BDirectorNov 14 '25Buy2.1115,00031,6502,470,539Nov 18 07:44 AM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 200
  • Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman (GlobeNewswire) +6.68%
  • Annovis Announces Pricing of $21.0 Million Public Offering (GlobeNewswire) -44.72%
  • Annovis Announces Launch of Proposed Public Offering (GlobeNewswire) +11.01%
  • Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE (GlobeNewswire) +10.78%
  • Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 (GlobeNewswire)
  • Annovis to Attend the CTAD 2026 with Three Presentations (GlobeNewswire)
  • Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease (GlobeNewswire)
  • Annovis to Host Corporate Update Webinar on September 2, 2026 (GlobeNewswire)
  • Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results (GlobeNewswire)
  • Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial (NYSE)
  • Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease (GlobeNewswire)
  • Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer (GlobeNewswire)
  • Annovis Bio Regains NYSE Listing Compliance (GlobeNewswire) -7.62%
  • Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants (GlobeNewswire) +5.15%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.400-0.453-0.3750.000.003
2026Q12026-05-15-0.630-0.395-0.6320.000.002
2025Q42026-03-16-0.390-0.308-0.3960.000.002
2025Q32025-11-12-0.370-0.377-0.3690.000.003
2025Q22025-08-12-0.320-0.403-0.3190.000.004
2025Q12025-05-13-0.320-0.410-0.3180.00-2
2024Q42025-03-21-0.430-0.272-0.4780.000.005
2024Q32024-11-11-0.970-0.683-0.9740.000.006
2024Q22024-08-15-0.440-0.628-0.4440.000.006
2024Q12024-05-13-0.720-0.817-0.1000.000.004
2023Q42024-04-04-2.271-1.776-2.3320.000.005
2023Q32023-11-08-1.630-1.090-1.6330.00-3
2023Q22023-08-14-1.070-1.140-1.065--3
2023Q12023-05-11-1.190-0.592-1.1880.000.002
2022Q42023-04-04-0.380-0.830-0.3790.000.003
2022Q32022-11-08-0.930-1.013-0.934-0.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3.510--0.1450.00-
2020FY-0.870--0.866--
2021FY-1.900-1.390-1.9000.00-
2022FY-3.100-3.550-3.1030.000.00
2023FY-6.228-5.655-6.2290.000.00
2024FY-2.310-1.915-2.3060.000.00
2025FY-1.400-1.305-1.3900.000.00
2026FY--1.407--0.00
2027FY--0.970--0.00
2028FY--1.515--50.53
2029FY-0.635--297.44
2030FY-4.080--619.05

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-142000.000.000.00
2026Q3S2026-07-062000.000.000.00
2026Q3S2026-05-151000.000.000.00
2026Q3S2026-03-161000.000.000.00
2026Q3S2025-11-121000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00
2026Q3S2025-11-021000.000.000.00
2026Q3S2025-11-011000.000.000.00
2026Q3S2025-10-311000.000.000.00
2026Q3S2025-10-301000.000.000.00
2026Q3S2025-10-291000.000.000.00

Estimate history

EPS, annual-0.1-0.105-0.145-0.866-1.9-3.103-6.229-2.306-1.404-1.7925
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.444-0.974-0.478-0.318-0.319-0.369-0.396-0.632-0.395
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual6.8186.8186.8456.8928.1018.16410.5214.14227.19942.606
Period201720182019202020212022202320242025MRQ
Shares, quarterly11.72113.28414.14219.48619.48620.18827.19928.53742.606
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other49.5329.7026.6945.0425.5114.546.641.610.71
Research and Development43.7725.2220.0038.7916.528.483.050.780.11
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-49.53-29.70-26.69-45.04-25.51-14.54-6.64-1.61-0.71
Interest Expense0.000.001.850.000.000.00-0.04-
Unusual Expense-0.98-0.14-3.6311.840.000.000.030.08-
Net Income Before Taxes-49.52-28.85-24.59-56.20-25.33-14.49-5.46-0.99-0.71
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-49.52-28.85-24.59-56.20-25.33-14.49-5.46-0.99-0.71
Net Income From Continuing Operations-49.52-28.85-24.59-56.20-25.33-14.49-5.46-0.99-0.71
Net Income-49.52-28.85-24.59-56.20-25.33-14.49-5.46-0.99-0.71
EPS (Recurring)-1.34-1.41-2.51-5.31-3.10-1.90-0.86-0.14-0.10
EPS (Basic, Before Extraordinaries)-1.79-1.40-2.02-6.23-3.10-1.90-0.87-0.14-0.10
EPS (Diluted)-1.79-1.40-2.31-6.23-3.10-1.90-0.87-0.14-0.10
EBITDA-49.53-29.70-26.69-45.04-25.51-14.54-6.64-1.61-0.71
Non-Operating Income (Expense)-0.970.700.330.670.180.051.200.740.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.591.803.844.639.154.701.740.010.08
Shares Outstanding42.6127.2014.1410.528.168.106.896.856.82
Market Capitalization36.4236.4269.40191.91109.64142.4151.9650.58-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other14.3818.019.717.436.276.286.734.39
Research and Development12.0116.728.756.295.165.015.002.69
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-14.38-18.01-9.71-7.43-6.27-6.28-6.73-4.39
Interest Expense0.000.000.000.000.000.000.000.52
Unusual Expense-0.99-0.270.30-0.020.14-0.56-0.737.86
Net Income Before Taxes-14.82-17.61-9.83-7.26-6.22-5.54-5.86-12.64
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-14.82-17.61-9.83-7.26-6.22-5.54-5.86-12.64
Net Income From Continuing Operations-14.82-17.61-9.83-7.26-6.22-5.54-5.86-12.64
Net Income-14.82-17.61-9.83-7.26-6.22-5.54-5.86-12.64
EPS (Recurring)-0.41-0.64-0.39-0.37-0.31-0.34-0.51-0.55
EPS (Basic, Before Extraordinaries)-0.40-0.63-0.40-0.37-0.32-0.32-0.43-0.97
EPS (Diluted)-0.40-0.63-0.40-0.37-0.32-0.32-0.48-0.97
EBITDA-14.38-18.01-9.71-7.43-6.27-6.28-6.73-4.39
Non-Operating Income (Expense)-1.430.140.170.150.190.190.140.14
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.610.180.360.440.500.501.480.39
Shares Outstanding42.6128.5427.2020.1919.4919.4914.1413.28
Market Capitalization36.4263.2391.7040.3442.2929.2369.40105.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments19.5310.555.7528.3845.698.070.000.040.35
Short Term Receivables0.000.000.000.000.000.000.740.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.553.374.457.640.320.040.010.020.01
Total Current Assets21.0813.9310.2136.0246.008.120.750.050.36
Net Property, Plant & Equipment0.000.000.000.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.370.000.00
Total Assets21.0813.9310.2136.0246.008.121.120.050.36
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.000.000.000.00
Accounts Payable2.592.311.293.960.690.341.230.070.07
Other Current Liabilities1.041.582.993.740.820.240.780.500.42
Total Current Liabilities3.643.884.287.701.510.582.010.570.49
Long Term Debt0.000.000.000.000.000.000.500.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.590.7413.680.000.000.000.110.000.00
Total Liabilities4.234.6217.967.701.510.582.620.570.49
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.007.087.086.83
Common Equity16.859.31-7.7528.3244.497.54-8.58-7.59-6.97
Total Shareholders Equity16.859.31-7.7528.3244.497.54-1.50-0.52-0.13
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity16.859.31-7.7528.3244.497.54-1.50-0.52-0.13
Total Liabilities & Stockholders Equity21.0813.9310.2136.0246.008.121.120.050.36
Book Value Per Share0.620.66-0.743.475.491.09-1.25-1.11-1.02
Tangible Book Value Per Share0.620.66-0.743.475.491.09-1.25-1.11-1.02
Full-Time Employees8865322--
Price to Book Ratio-8.549.4625.313.663.206.895.53--
Return on Assets-164.85-203.78-243.15-61.76-53.54-118.27-169.67-349.12-
Return on Equity-220.61-3,159.09-546.40-69.57-55.68-180.82---
Return on Invested Capital-171.23-264.20--89.43-32.56-72.43---
Quick Ratio5.803.592.394.6830.5414.040.370.090.73
Current Ratio5.803.592.394.6830.5414.040.370.090.73

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-49.52-28.85-24.59-56.20-25.33-14.49-5.46-0.99-0.71
Other Funds (Non Cash)1.611.662.0116.479.154.701.890.090.08
Funds from Operations-47.91-27.20-22.58-39.74-16.18-9.79-3.57-0.90-0.63
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital4.571.580.68-0.23-1.140.66-0.400.420.07
Cash from Operating Activities-43.34-25.62-21.89-39.97-17.31-9.13-3.97-0.48-0.56
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock44.9434.6026.6917.340.0046.740.01-0.080.25
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock44.9434.6026.6917.340.0046.740.01-0.080.25
Proceedsfrom Stock Options44.9234.6026.6917.340.0046.650.01-0.080.25
Issuance or Reduction of Debt, Net0.000.000.000.000.000.0012.030.520.00
Change in Long Term Debt0.000.000.000.000.000.0012.030.520.00
Issuance of Long Term Debt0.000.000.000.000.000.0012.030.520.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities44.9434.6026.6917.340.0046.7412.040.440.25
Net Change in Cash1.608.984.80-22.62-17.3137.618.07-0.03-0.31
Free Cash Flow-43.34-25.62-21.89-39.97-17.31-9.13-3.97-0.48-0.56
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments18.7314.2219.5315.2917.1322.24
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.312.021.551.904.324.50
Total Current Assets22.0416.2421.0817.1921.4526.74
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets22.0416.2421.0817.1921.4526.74
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable3.335.282.592.110.971.37
Other Current Liabilities3.037.511.041.621.831.13
Total Current Liabilities6.3612.793.643.732.812.50
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities19.930.330.590.300.320.18
Total Liabilities26.2913.124.234.033.122.68
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-4.253.1316.8513.1618.3324.05
Total Shareholders Equity-4.253.1316.8513.1618.3324.05
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-4.253.1316.8513.1618.3324.05
Total Liabilities & Stockholders Equity22.0416.2421.0817.1921.4526.74
Book Value Per Share-0.100.110.620.650.941.23
Tangible Book Value Per Share-0.100.110.620.650.941.23
Full-Time Employees--8---
Price to Book Ratio-8.543.605.312.201.762.28
Return on Assets-227.74-190.43-164.85-157.74-228.37-168.22
Return on Equity-703.68-301.13-220.61-246.14-365.03-280.78
Return on Invested Capital--563.21-58.36-55.20-33.93-23.02
Quick Ratio3.471.275.804.607.6510.68
Current Ratio3.471.275.804.607.6510.68

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-14.82-17.61-9.83-7.26-6.22-5.54
Other Funds (Non Cash)0.62-0.090.650.420.64-0.06
Funds from Operations-14.20-17.69-9.18-6.84-5.58-5.60
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-7.728.680.253.350.48-2.50
Cash from Operating Activities-21.91-9.01-8.93-3.49-5.11-8.10
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock26.423.7013.171.640.0019.78
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock26.423.7013.171.640.0019.78
Proceedsfrom Stock Options26.413.7013.171.640.0019.78
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities26.423.7013.171.640.0019.78
Net Change in Cash4.51-5.314.25-1.84-5.1111.68
Free Cash Flow-21.91-9.01-8.93-3.49-5.11-8.10

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3014.23%5.4M37.7M895.43K
2026-10-1515.19%5.7M37.7M857.62K
2026-09-3015.66%5.9M37.6M921.75K
2026-09-1516.00%6.0M37.6M907.60K
2026-08-3113.18%5.0M37.9M802.26K
2026-08-1413.11%5.0M37.9M966.70K
2026-07-3113.73%5.2M37.8M1.03M
2026-07-1514.42%5.5M37.8M1.11M
2026-06-3013.24%4.9M36.7M1.22M
2026-06-1513.08%4.8M36.7M1.15M
2026-05-2916.79%5.0M29.9M1.00M
2026-05-1515.63%4.7M29.9M826.81K
2026-04-3015.47%4.8M31.1M723.84K
2026-04-1516.30%4.8M29.2M648.38K
2026-03-3113.49%3.2M24.0M442.98K
2026-03-1311.59%2.8M24.0M434.88K
2026-02-2712.25%2.7M22.4M577.47K
2026-02-1312.64%2.8M22.4M1.63M
2026-01-3013.10%2.9M22.4M1.64M
2026-01-1513.98%3.1M22.4M1.66M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.750.3517.21585329.000.874-0.0320.000
call1.000.000.900.146.4411040.000.442-0.0410.000
call1.500.000.050.057.94617.000.000.231-0.0370.000
call2.000.004.900.009.6300.000.000.201-0.0410.000
call2.500.004.900.0011.1530.000.000.186-0.0440.000
put0.500.000.750.059.43632.000.00-0.126-0.0320.000
put1.000.004.900.100.0001000.00-0.320-0.1000.000
put1.500.104.900.000.0000.000.00-0.768-0.0390.000
put2.000.455.000.000.0000.000.00-0.801-0.0460.000
put2.500.355.000.000.0000.000.00-0.817-0.0500.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-064Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-05424B5SEC
2026-11-04424B5SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-11-048-KCurrent report2026-11-03SEC
2026-10-308-KCurrent report2026-10-29SEC
2026-10-208-KCurrent report2026-10-19SEC
2026-10-15SCHEDULE 13G/ASEC
2026-10-07DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-11DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-14SEC
2026-08-25PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-24SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14SCHEDULE 13GSEC
2026-07-29SCHEDULE 13GSEC
2026-07-108-KCurrent report2026-07-07SEC
2026-06-178-KCurrent report2026-06-17SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-208-KCurrent report2026-05-20SEC
2026-05-20424B5SEC
2026-05-19424B5SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-17SEC
2026-04-108-KCurrent report2026-04-09SEC
2026-04-09424B5SEC
2026-04-034Statement of changes in beneficial ownership of securities2026-04-02SEC
2026-04-02144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-115.00M100
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-05142.78K100
2026-041.50M100
2026-030000
2026-020000
2026-010000
2025-12193.79K100
2025-11261.44K300

Institutional holders

Manager% owned
Empery Asset Management, LP5.64%
MARSHALL WACE, LLP4.33%
VANGUARD CAPITAL MANAGEMENT LLC3.87%
TUDOR INVESTMENT CORP ET AL3.19%
RENAISSANCE TECHNOLOGIES LLC2.36%
TWO SIGMA INVESTMENTS, LP1.36%
GEODE CAPITAL MANAGEMENT, LLC0.76%
BlackRock, Inc.0.59%
CITADEL ADVISORS LLC0.57%
VANGUARD FIDUCIARY TRUST CO0.42%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.87%
VANGUARD EXTENDED MARKET INDEX FUND0.93%
Fidelity Extended Market Index Fund0.36%
iShares Micro-Cap ETF0.24%
Fidelity Series Total Market Index Fund0.11%
Fidelity Total Market Index Fund0.10%
Ultra-Small Company Market Fund0.08%
VANGUARD BALANCED INDEX FUND0.05%
Dimensional U.S. Small Cap ETF0.04%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.03%

OakChart. ANVS. Cached 15 minutes.